GE1111 是一种 MRGPRX2 拮抗剂(IC50 = 9.4 μM),可抑制 MRGPRX2/MRGPRB2 介导的肥大细胞激活,降低 TSLP、IL-13、MCP-1、TNF-α、IL-1β 和 periostin 的表达,维持 claudin 1 和 involucrin 的表达水平,恢复巨噬细胞的吞噬活性,并减弱 STIM1 和磷酸化 AKT 的活化,从而在多种动物模型中发挥抗炎、抗过敏作用,可用于玫瑰痤疮、特应性皮炎和溃疡性结肠炎的相关研究。
产品编号: MS-U21627 纯度: 95.73% CAS No.: 2883669-12-1 分子式: C28H22N2O5 分子量: 466.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

GE1111 是一种 MRGPRX2 拮抗剂(IC50 = 9.4 μM),可抑制 MRGPRX2/MRGPRB2 介导的肥大细胞激活,降低 TSLP、IL-13、MCP-1、TNF-α、IL-1β 和 periostin 的表达,维持 claudin 1 和 involucrin 的表达水平,恢复巨噬细胞的吞噬活性,并减弱 STIM1 和磷酸化 AKT 的活化,从而在多种动物模型中发挥抗炎、抗过敏作用,可用于玫瑰痤疮、特应性皮炎和溃疡性结肠炎的相关研究。

生物实验数据

生物活性 GE1111 is an MRGPRX2 antagonist (IC50 = 9.4 μM) that inhibits MRGPRX2/MRGPRB2-mediated mast cell activation, reduces the expression of TSLP, IL-13, MCP-1, TNF-α, IL-1β, and periostin, maintains the expression levels of claudin 1 and involucrin, restores macrophage phagocytic activity, and attenuates STIM1 and phosphorylated AKT activation, thereby exerting anti-inflammatory and anti-allergic effects in multiple animal models and being applicable for research on rosacea, atopic dermatitis, and ulcerative colitis.
IC50 & Target

IC50: 9.42 μM (MRGPRX2)

体外研究
(In Vitro)

GE1111 可强效抑制 LL-37 诱导的 LAD-2 人肥大细胞脱颗粒,其 IC50 为 6.271 μM。
GE1111 (30 min) 抑制转染了 MRGPRX2 的 HEK-293 细胞中由 LL-37 诱导的 MRGPRX2 介导的钙内流,IC50 为 12.31 μM。
GE1111 (50 μM;30 分钟) 可在人肥大细胞 LAD-2 中抑制 LL-37 诱导的 MRGPRX2 下游信号通路 (STIM1、ERK 1/2) 激活,并降低促炎细胞因子基因 (IL-31、MCP-1、TNF-α) 的表达。
GE1111 (50 μM;2 h) 可恢复暴露于肥大细胞条件培养基的人角质形成细胞 HaCaT 中的 claudin-1 表达,减少促炎性 TSLP 的表达,并降低促炎性细胞因子基因 (IL-8、IL-13、IL-17) 的表达。
GE1111 (50 μM;2 h) 可恢复被 LL-37 刺激的肥大细胞条件培养基损伤的 RAW 264.7 小鼠巨噬细胞的吞噬功能。
GE1111 (0.01 nM-100 μM;1 小时) 是转染 Mrgprx2 HTLA 细胞中 MRGPRX2 的反向激动剂和拮抗剂,降低基础 β-抑制蛋白募集水平以及激动剂诱导的 β-抑制蛋白募集水平。
GE1111 (100 μM; 1 h) 可诱导 LAD2 肥大细胞中 MRGPRX2 的内化。

Western Blot Analysis

Cell Line: LAD2 cells
Concentration: 50 μM
Incubation Time: 30 min
Result: Reduced pERK1/2 levels compared to control when treated alone.
Significantly inhibited agonist-induced increases in pERK1/2 phosphorylation and STIM1 expression.

Immunofluorescence

Cell Line: LAD-2 MCs and
HaCaT keratinocytes
Concentration: 50 μM
Incubation Time: 2 h
Result: Increased claudin 1 expression and Reduced TSLP expression.

Western Blot Analysis

Cell Line: LAD-2 MCs and HaCaT keratinocytes
Concentration: 50 μM
Incubation Time: 2 h
Result: Exhibited a significant reduction
in the gene expression of inflammatory cytokines induced
by LL-37, compared to the group treated only with LL-37
MCs supernatant IL-8, IL-13 and IL-17.

Immunofluorescence

Cell Line: LAD-2 MCs and RAW 264.7 cells
Concentration: 50 μM
Incubation Time: 2 h
Result: Mitigated the
negative effects of LL-37 on macrophage function.
体内研究
(In Vivo)

GE1111 (10-20 mg/kg; i.p.; daily; 6 days) 可通过抑制肥大细胞脱颗粒、恢复皮肤屏障功能及降低全身和局部炎症介质,减轻 LL-37 诱导小鼠的酒渣鼻样炎症。
GE1111 (20 mg/kg; i.p.; single pre-treatment) 可抑制肥大细胞脱颗粒改善 compound 48/80 (MS-A26686) 诱导的小鼠瘙痒。
GE1111 (10-20 mg/kg;i.p.;每周;持续 4 周) 可通过减轻皮肤炎症、抑制肥大细胞脱颗粒、下调炎症介质表达及恢复表皮屏障蛋白表达,显著缓解小鼠中由 DNFB 诱导的特应性皮炎。
GE1111 (300 µg/kg;i.p.;隔日 1 次;12 天) 可提高经 4% DSS (MS-A45736) 诱导溃疡性结肠炎的 C57BL/6N 小鼠的存活率,可通过恢复结肠完整性、使细胞因子水平恢复正常、减少免疫细胞浸润以及降低结肠 Mrgprb2/Mrgpra1 的表达,缓解经 2.5% DSS 诱导溃疡性结肠炎的 C57BL/6N 小鼠的发病严重程度。

Animal Model: C57BL/6N wild-type adult male (6 to 8 weeks old, LL-37-induced rosacea model); MRGPRB2 knock-out adult male (6 to 8 weeks old, LL-37-induced rosacea model)
Dosage: 10 mg/kg; 20 mg/kg
Administration: i.p.; daily; 6 days
Result: Reduced skin redness/damage severity scores.
Reduced serum MCP-1 levels, epidermal thickness, and the percentage of degranulated mast cells in skin tissue.
Restored the expression of epidermal barrier proteins involucrin and claudin-1, and reduces the expression of STIM1 and TSLP proteins.
Reduced gene expression of inflammatory cytokines IL-13, IL-33, MCP-1, IL-1β, and TNF-α in skin tissue.
Animal Model: C57BL/6N wild-type adult male; MRGPRB2 knock-out adult male (compound 48/80-induced itch model)
Dosage: 20 mg/kg
Administration: i.p.; single dose 30 minutes prior to compound 48/80 injection
Result: Reduced the number and total duration of scratching episodes compared to compound 48/80-treated control mice, without affecting the average length of individual scratches.
Reduced the percentage of degranulated mast cells in skin tissue relative to compound 48/80-treated controls.
Animal Model: BALB/c (male, 6 to 8 weeks old, DNFB-induced atopic dermatitis)
Dosage: 10 mg/kg; 20 mg/kg
Administration: i.p.; once weekly; 4 weeks
Result: Reduced skin thickening scores, erythema scores, and epidermal thickness in the skin and ear.
Significantly reduced skin scaling scores in the 10 mg/kg dose group.
Reduced serum MCP-1 levels and skin TSLP protein expression in the 20 mg/kg dose group.
Reduced the percentage of degranulated mast cells in ear tissue, maintained skin capsule protein expression, and reduced skin periosteal protein expression.
Reduced gene expression of TSLP, IL-13, and IL-1β in the skin, and reduced protein expression of STIM1 and p-AKT in the skin.
Significantly increased claudin 1 protein expression in the skin.
Animal Model: C57BL/6N (adult male, 6-8 weeks old, 2.5-4% dextran sulfate sodium-induced colitis)
Dosage: 300 µg/kg
Administration: i.p.; every alternative day; Day 0 to Day 12
Result: Increased the survival rate of mice subjected to 4% DSS-induced colitis.
Reduced body weight and Disease Activity Index (DAI) score.
Restored colon length, reduced colon weight/length ratio, and decreased intestinal permeability (reduced FITC-glucan fluorescence intensity in plasma).
Reduced colonic erosion and histological damage, restored colonic integrity genes claudin 1, occludin, and E-cadherin mRNA expression, and reduced VEGF mRNA expression.
Restored claudin 1 protein expression in colonic tissue, reduced plasma M-CSF, G-CSF, and BLC concentrations, and partially restored plasma sTNF RI concentration.
Reduced CD68+ and F4/80+ immune cell infiltration in the colon and reduced colonic COX-2 expression.
Reduced Mrgpra1 and Mrgprb2 mRNA expression in colonic tissue.
性状 固体
颜色 Yellow to orange

化学信息

分子量 466.48
分子式 C28H22N2O5
CAS No. 2883669-12-1

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (214.37 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.1437 mL10.7186 mL21.4371 mL53.5929 mL
5 mM0.4287 mL2.1437 mL4.2874 mL10.7186 mL
10 mM0.2144 mL1.0719 mL2.1437 mL5.3593 mL
15 mM0.1429 mL0.7146 mL1.4291 mL3.5729 mL
20 mM0.1072 mL0.5359 mL1.0719 mL2.6796 mL
25 mM0.0857 mL0.4287 mL0.8575 mL2.1437 mL
30 mM0.0715 mL0.3573 mL0.7146 mL1.7864 mL
40 mM0.0536 mL0.2680 mL0.5359 mL1.3398 mL
50 mM0.0429 mL0.2144 mL0.4287 mL1.0719 mL
60 mM0.0357 mL0.1786 mL0.3573 mL0.8932 mL
80 mM0.0268 mL0.1340 mL0.2680 mL0.6699 mL
100 mM0.0214 mL0.1072 mL0.2144 mL0.5359 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础